文献速递妇科

宫颈上皮内瘤变2级主动监测的已知获益与未知风险

Known Benefits and Unknown Risks of Active Surveillance of Cervical Intraepithelial Neoplasia Grade 2.
PubMed 文献 · Obstet Gynecol · 2022-03-10

宫颈上皮内瘤变2级(CIN 2)诊断一致性差,自然消退率约50%,25-30岁以下女性更高达60%,多国推荐主动监测。主动监测通常为每半年随访一次、最长2年,含阴道镜及细胞学或HPV检测,2年后进展或持续病变推荐切除治疗。年轻女性主动监测较新,后续宫颈癌风险及生物标志物风险分层价值尚不明确。

要点

  • CIN 2自然消退率约50%,25-30岁以下女性约60%,多国推荐主动监测。
  • 主动监测通常为每半年随访一次、最长2年,含阴道镜及细胞学或HPV检测。
  • 2年后进展或持续病变推荐切除治疗;p16免疫组化目前用于辅助组织学诊断。

核心结论

  • CIN 2主动监测需进一步研究,包括了解长期宫颈癌风险和评估可能实现CIN 2风险分层的标志物。

研究设计与样本

  • 原文为综述,未报告系统检索范围。

主要发现

  • CIN 2诊断存在高度观察者间差异,自然消退率约50%,25-30岁以下女性消退率更高(即60%)。
  • 切除治疗与生殖危害风险增加相关,尤其是早产。
  • 年轻女性主动监测相对较新,关于后续宫颈癌风险的知识有限。
  • 考虑人乳头瘤病毒潜伏,接受主动监测的女性宫颈癌风险可能高于接受切除治疗者。
  • 描述女性对CIN 2管理偏好的数据有限,主动监测如何影响未来妊娠计划也不清楚。

关键数值与推荐

  • 许多国家推荐对CIN 2进行主动监测,尤其是25-30岁以下女性,其消退率更高(即60%)。
  • 主动监测通常包括每半年随访一次、最长2年,含阴道镜及细胞学、人乳头瘤病毒检测或两者。
  • 2年后进展或持续病变推荐切除治疗。
  • 目前p16免疫组化染色用于辅助组织学诊断,但其或其他生物标志物能否用于CIN 2临床管理中的风险分层仍未知。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 年轻女性主动监测相对较新,关于后续宫颈癌风险的知识有限。
  • 描述女性对CIN 2管理偏好的数据有限。
  • 主动监测如何影响未来妊娠计划不清楚。
  • p16或其他生物标志物能否用于CIN 2风险分层仍未知。
  • CIN 2主动监测需进一步研究,包括了解长期宫颈癌风险和评估风险分层标志物。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Cervical intraepithelial neoplasia grade 2 (CIN 2) is an equivocal diagnosis with high interobserver variation. Owing to high regression rates of 50%, many countries recommend active surveillance of CIN 2, especially in women younger than age 25-30 years, where regression rates are even higher (ie, 60%). Additionally, excisional treatment is associated with increased risk of reproductive harm, particularly preterm birth. Active surveillance typically consists of semi-annual follow-up visits for up to 2 years, including colposcopy and either cytology, testing for human papillomavirus, or both. Excisional treatment is recommended for progression or persistent disease after 2 years. Because active surveillance in younger women is relatively new, knowledge on subsequent risk of cervical cancer is limited. Considering human papillomavirus latency, women undergoing active surveillance might be at higher risk of cervical cancer than women undergoing excisional treatment. Furthermore, there are limited data describing preferences of women for the management of CIN 2, and it is also unclear how active surveillance may affect planning for future pregnancy. In this context, biomarkers for risk stratification of CIN 2 into either high or low probability of progression would allow for targeted treatment. Currently, immunohistochemical staining for p16 is used to clarify the histologic diagnosis, but whether it or other biomarkers can be used for risk-stratification in clinical management of women with CIN 2 remains unknown. In conclusion, active surveillance of CIN 2 needs further investigation, including understanding the long-term cervical cancer risk and evaluation of markers that may enable risk stratification of CIN 2.

来源:Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Lycke KD, Petersen LK, Gravitt PE, et al. Known Benefits and Unknown Risks of Active Surveillance of Cervical Intraepithelial Neoplasia Grade 2. Obstet Gynecol. 2022. PMID: 35271554. doi:10.1097/AOG.0000000000004705

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。